INFINITI KRAS-BRAF Assay
Sample Type and Volume:
- KRAS mutations are present in >45% of colorectal adenomas and carcinomas, while BRAF is present in about 12%.
- Common in the following cancers:
- Colorectal (primarily)
- Gall Bladder
- Bile Duct
- Mutations may indicate prognosis and drug response to Cancer therapies (anti-EGFR drugs - Cetuximab/Erbitux, Panitumumab/Vectibix, Gefitinib/Iressa, Erlotinib/Tarceva).
- Identification of KRAS & BRAF mutations suggest that anti-EGFR therapies will not work in most, if not all patients.
- ASCO and other cancer organizations are recommending that all patients with metastatic colorectal cancer who are considering anti-EGFR therapies should be tested for KRAS mutation status.
- Kahn S, Yamamoto F, Almoguera C, Winter E, Forrester K, Jordano J, Perucho M (1987). "The c-K-ras gene and human cancer (review)". Anticancer Res. 7 (4A): 639–52. PMID 3310850.
- Yamamoto F, Nakano H, Neville C, Perucho M (1985). "Structure and mechanisms of activation of c-K-ras oncogenes in human lung cancer". Prog. Med. Virol. 32: 101–14. PMID 3895297.
- Garnett MJ, Marais R (2004). "Guilty as charged: B-Raf is a human oncogene". Cancer Cell 6 (4): 313–9. doi:10.1016/j.ccr.2004.09.022. PMID 15488754.
- Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X (2005). "Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations". Cancer 103 (11): 2261–8. doi:10.1002/cncr.21073. PMID 15880523.